Spring Bank Pharmaceuticals (NASDAQ:SBPH) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Friday.

Several other equities research analysts also recently issued reports on SBPH. Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, August 7th. Chardan Capital reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Sunday, September 17th. B. Riley assumed coverage on Spring Bank Pharmaceuticals in a research note on Monday, November 6th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald set a $29.00 price objective on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Spring Bank Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $27.25.

Shares of Spring Bank Pharmaceuticals (NASDAQ SBPH) opened at $13.50 on Friday. Spring Bank Pharmaceuticals has a one year low of $6.31 and a one year high of $18.93.

Several institutional investors and hedge funds have recently bought and sold shares of SBPH. Morse Asset Management Inc raised its stake in shares of Spring Bank Pharmaceuticals by 156.9% during the 2nd quarter. Morse Asset Management Inc now owns 63,700 shares of the company’s stock worth $862,000 after purchasing an additional 38,900 shares in the last quarter. C WorldWide Group Holding A S purchased a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter worth about $340,000. Sphera Funds Management LTD. purchased a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter worth about $2,370,000. AXA purchased a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter worth about $2,894,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Spring Bank Pharmaceuticals during the 2nd quarter worth about $794,000. 29.70% of the stock is owned by institutional investors.

WARNING: “Spring Bank Pharmaceuticals (SBPH) Cut to “Sell” at ValuEngine” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/02/spring-bank-pharmaceuticals-sbph-cut-to-sell-at-valuengine.html.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.